Editors
Veronika Ballová Onkologie Kantonsspital, Baden, Switzerland
Meletios-Athanasios Dimopoulos National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
Michele Ghielmini IOSI – Oncology Institute of Southern Switzerland
Contributors
Chapter 1. Diagnosis and classification of leukaemias
T. Haferlach MLL – Munich Leukemia Laboratory, Munich, Germany
A. Höllein MLL – Munich Leukemia Laboratory, Munich, Germany
Chapter 2. Acute myeloid leukaemia
U. Bacher Department of Hematology, Inselspital Bern, Bern, Switzerland
T. Pabst Department of Oncology, Inselspital Bern, Bern, Switzerland
G. Stüssi Department of Hematology, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, Bellinzona, Switzerland
Chapter 3. Acute lymphoblastic leukaemia
N. Gökbuget Goethe University Hospital, Department of Medicine II, Frankfurt am Main, Germany
Chapter 4. Chronic myeloid leukaemia
G.M. Baerlocher Clinical Stem Cell Laboratory and Molecular Hematology, INSELSPITAL, University Hospital Bern, Bern, Switzerland
Chapter 5. Myelodysplastic syndromes
P. Fenaux Hematology Department, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, Paris, France
R. Itzykson Hematology Department, INSERM U944, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, Paris, France
Chapter 6. Classification, diagnosis and response assessment of myeloma
H. Avet-Loiseau CRCT INSERM U1037; Laboratory for Genomics in Myeloma, University Cancer Centre of Toulouse, Toulouse, France
J. Corre CRCT INSERM U1037; Laboratory for Genomics in Myeloma, University Cancer Centre of Toulouse, Toulouse, France
Chapter 7. Newly diagnosed myeloma, transplant-eligible patients
M. Cavo “Seràgnoli” Institute of Hematology and Medical Oncology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, Bologna, Italy
P. Tacchetti “Seràgnoli” Institute of Hematology and Medical Oncology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, Bologna, Italy
E. Zamagni “Seràgnoli” Institute of Hematology and Medical Oncology, Department of Experimental, Diagnostic and Specialty Medicine, Bologna University School of Medicine, Bologna, Italy
Chapter 8. Newly diagnosed myeloma, transplant-ineligible patients
I.S. Nijhof Department of Hematology, Amsterdam UMC, Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, Netherlands
C. Stege Department of Hematology, Amsterdam UMC, Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, Netherlands
S. Zweegman Department of Hematology, Amsterdam UMC, Vrije Universiteit, Cancer Center Amsterdam, Amsterdam, Netherlands
Chapter 9. Relapsed and refractory multiple myeloma
M.A. Dimopoulos Alexandra Hospital, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
M. Gavriatopoulou Alexandra Hospital, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
E. Kastritis Alexandra Hospital, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece
Chapter 10. Symptomatic therapy and management of complications in myeloma
V. González-Calle Department of Hematology, University Hospital of Salamanca/IBSAL, Salamanca, Spain
M.V. Mateos Department of Hematology, University Hospital of Salamanca/IBSAL, Salamanca, Spain
E.M. Ocio Department of Hematology, Hospital Universitario Marqués de Valdecilla/University of Cantabria, Santander, Spain
P. Rodríguez-Otero Clinica Universidad Navarra, CIMA, IDISNA, Ciberonc, Spain
Chapter 11. Molecular biology of leukaemia
M. Dawidowska Institute of Human Genetics, Polish Academy of Sciences, Poznań, Poland
M. Witt Institute of Human Genetics, Polish Academy of Sciences, Poznań, Poland
Chapter 12. Molecular biology of myeloma
D. Hofste op Bruinink Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
P. Sonneveld Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
Chapter 13. Allogeneic transplantation and graft-versus-host disease
A. Grassi Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII Bergamo, Bergamo, Italy
F. Lussana Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII Bergamo, Bergamo, Italy
A. Rambaldi Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII Bergamo, Bergamo; University of Milan, Department of Oncology and Hemato-oncology, Milan, Italy
Chapter 14. Myeloproliferative neoplasms other than chronic myeloid leukaemia: essential thrombocythaemia, polycythaemia vera and myelofibrosis
A. Álvarez-Larrán Hematology Department, Hospital Clinic, IDIBAPS, University of Barcelona, Barcelona, Spain
F. Cervantes Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain
Chapter 15. Myelodysplastic/myeloproliferative diseases
M. Duchmann UMR 1170, Gustave Roussy, Villejuif, France
R. Itzykson Hematology Department, INSERM U944, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université Paris Diderot, Paris, France
N. Lucas UMR 1170, Gustave Roussy, Villejuif, France
E. Solary UMR 1170, Gustave Roussy, Villejuif, France
Chapter 16. New drugs and novel treatment strategies in acute leukaemia
C. Lengerke Division of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland
M. Medinger Division of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland
J.R. Passweg Division of Hematology, Department of Medicine, University Hospital Basel, Basel, Switzerland
Chapter 17. New drugs and novel treatment strategies in multiple myeloma treatment
E.M. Ocio Department of Hematology, Hospital Universitario Marqués de Valdecilla/University of Cantabria, Santander, Spain
M.V. Mateos Department of Hematology, University Hospital of Salamanca/IBSAL, Salamanca, Spain
P. Rodríguez-Otero Clinica Universidad Navarra, CIMA, IDISNA, Ciberonc, Spain
J.F. San Miguel Clinica Universidad Navarra, CIMA, IDISNA, Ciberonc, Spain
Chapter 18. Systemic immunoglobulin light-chain amyloidosis
A.D. Wechalekar National Amyloidosis Centre, University College London (Royal Free Campus), London, UK
Declarations of Interest
Chapter 1. Diagnosis and classification of leukaemias
T. Haferlach: Equity ownership of Munich Leukemia Laboratory (MLL), Munich, Germany.
A. Höllein: Employed by Munich Leukemia Laboratory (MLL).
Chapter 2. Acute myeloid leukaemia
U. Bacher: No conflicts of interest.
T. Pabst: No conflicts of interest.
G. Stüssi: No conflicts of interest.
Chapter 3. Acute lymphoblastic leukaemia
N. Gökbuget: Advisory boards / honoraria for Amgen, Pfizer, Novartis, Kite, Incyte, Servier; research support from Amgen, Pfizer, Incyte Novartis, Servier.
Chapter 4. Chronic myeloid leukaemia
G.M. Baerlocher: Advisory Boards for Novartis, Bristol-Myers Squibb, Pfizer, Ariad, Incyte; research funding from Geron Corporation.
Chapter 5. Myelodysplastic syndromes
P. Fenaux: No conflicts of interest.
R. Itzykson: No conflicts of interest.
Chapter 6. Classification, diagnosis and response assessment of myeloma
H. Avet-Loiseau: No conflicts of interest.
J. Corre: No conflicts of interest.
Chapter 7. Newly diagnosed myeloma, transplant-eligible patients
M. Cavo: Honoraria from and advisory boards for Celgene, Janssen, Takeda, Amgen, Bristol-Myers Squibb.
P. Tacchetti: No conflicts of interest.
E. Zamagni: No conflicts of interest.
Chapter 8. Newly diagnosed myeloma, transplant-ineligible patients
I.S. Nijhof: No conflicts of interest.
C. Stege: No conflicts of interest.
S. Zweegman: Advisory boards for Celgene, Janssen, Takeda, Amgen; research support from Celgene, Janssen, Takeda.
Chapter 9. Relapsed and refractory multiple myeloma
M.A. Dimopoulos: Consultancy for Janssen, Genesis, Celgene, Onyx, Amgen, Novartis.
M. Gavriatopoulou: No conflicts of interest.
E. Kastritis: Honoraria from Janssen, Genesis Pharma, Amgen, Takeda.
Chapter 10. Symptomatic therapy and management of complications in myeloma
V. González-Calle: No conflicts of interest.
M.V. Mateos: Consultancy for Janssen, Celgene, Takeda, Amgen.
E.M. Ocio: Consultancy for or honoraria from Mundipharma, Celgene, Amgen, Novartis, Takeda, AbbVie, Bristol-Myers Squibb, Janssen.
P. Rodríguez-Otero: No conflicts of interest.
Chapter 11. Molecular biology of leukaemia
M. Dawidowska: No conflicts of interest.
M. Witt: No conflicts of interest.
Chapter 12. Molecular biology of myeloma
D. Hofste op Bruinink: No conflicts of interest.
P. Sonneveld: Research support from Amgen, Celgene, Janssen, Karyopharm, SkylineDx; Advisory boards for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Karyopharm.
Chapter 13. Allogeneic transplantation and graft-versus-host disease
A. Grassi: No conflicts of interest.
F. Lussana: No conflicts of interest.
A. Rambaldi: No conflicts of interest.
Chapter 14. Myeloproliferative neoplasms other than chronic myeloid leukaemia: essential thrombocythaemia, polycythaemia vera and myelofibrosis
A. Álvarez-Larrán: No conflicts of interest.
F. Cervantes: No conflicts of interest.
Chapter 15. Myelodysplastic/myeloproliferative diseases
M. Duchmann: No conflicts of interest.
R. Itzykson: No conflicts of interest.
N. Lucas: No conflicts of interest.
E. Solary: No conflicts of interest.
Chapter 16. New drugs and novel treatment strategies in acute leukaemia
C. Lengerke: No conflicts of interest.
M. Medinger: No conflicts of interest.
J.R. Passweg: No conflicts of interest.
Chapter 17. New drugs and novel treatment strategies in multiple myeloma treatment
E.M. Ocio: Consultancy for or honoraria from Mundipharma, Celgene, Amgen, Novartis, Takeda, AbbVie, Bristol-Myers Squibb, Janssen.
M.V. Mateos: Consultancy for Janssen, Celgene, Takeda, Amgen.
P. Rodríguez-Otero: No conflicts of interest.
J.F. San Miguel: Consultancy for Janssen, Celgene, Takeda, Amgen, MSD, Bristol-Myers Squibb, Novartis.
Chapter 18. Systemic immunoglobulin light-chain amyloidosis
A.D. Wechalekar: No conflicts of interest.
